A new paradigm in osteoarthritis treatment Scott Williams,...

A new paradigm in osteoarthritis treatment​

Scott Williams, Fiftyone Capital ​

Without a doubt Paradigm (PAR) is still the best microcap opportunity we can identify. The risk/return profile for the company from this level now they are fully funded with successful Phase 2b trial results in osteoarthritis is being completely missed by the market. This is a company we have done extensive research on and published to our investors as well as on Livewire.​

The company has numerous upcoming catalysts including the treatment of Ex-NFL players in the US, which should significantly boost the profile of the business to US based pharma investors. Submissions for their IND to the FDA on two different trials (OA & MPS) and the potential for near term revenue from TGA provisional approvals in Australia that would result in treatment becoming available prior to passing the phase 3 trials.​

Probably the biggest catalyst though would be any potential pharma deal which we think could compare against the novel (but failed compound) Anti-NGF drug deal sizes that were in the $1b-$2b range. It should be an exciting 6 to 12 months for the company.​

https://www.livewiremarkets.com/wires/6-small-stocks-with-big-futures​